Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetesGlobeNewsWire • 08/22/22
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Joergensen on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
Novo Nordisk's Obesity Sales Nearly Doubled, But That Wasn't Enough For NVO StockInvestors Business Daily • 08/03/22
Novo Nordisk's sales increased by 25% in Danish kroner and by 16% at constant exchange rates to DKK 83.3 billion in the first six months of 2022GlobeNewsWire • 08/03/22
Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3GlobeNewsWire • 07/29/22
Novo Nordisk A/S: Mim8 phase 1 & 2 data demonstrates potential as once monthly treatment for people with haemophilia AGlobeNewsWire • 07/11/22
Echosens and Novo Nordisk Announce Partnership to Increase Awareness and Advance Early Diagnosis of NASHBusiness Wire • 06/22/22
Johnson & Johnson Or Novo Nordisk: Which Is The Best Big Pharma Near Cap-GainerSeeking Alpha • 06/16/22